Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, has announced an important new finding from its Phase I/II clinical trial of PLacental eXpanded cells in the treatment of muscle injury after total hip arthroplasty . Data showed that six months after surgery the magnitude of improvement in muscle force of the contralateral gluteal muscle was approximately 40 times larger in patients treated with 150 million PLX-PAD cells than in those who received placebo, and the difference was statistically significant .
http://ift.tt/1zxlE07
http://ift.tt/1zxlE07
No comments:
Post a Comment